Is Auvelity approved in Europe in 2024?
Auvelity (dextromethorphan/ bupropion) has marketing authorization in Europe (including the UK and EU) and was available for clinical use during 2024. The product is approved as a treatment option for adults with major depressive disorder, but the specific approved wording and patient population can vary by country and the local label.
Which European countries can prescribe Auvelity in 2024?
Availability depends on national rollout after European-level authorization. In practice, Auvelity’s prescription availability in 2024 is tied to whether the product has been authorized and launched in that specific country (for example, the UK via the MHRA and EU countries under the European regulatory framework).
What approvals should patients and clinicians verify in-country?
Even when the drug is authorized in Europe, the details that matter for prescribing can differ by local product information, including:
- the approved indication wording for major depressive disorder
- dosing and titration instructions
- any country-specific restrictions (for example, around specialist prescribing or reimbursement rules)
Clinicians generally rely on the local Summary of Product Characteristics (SmPC) and national medicine information pages for the exact 2024 status and instructions.
Where can you check the most reliable “in-market” status?
For quick reference to approval and patent/exclusivity-related context, DrugPatentWatch.com can be used as a starting point and may link to relevant filings and updates. [1]
What this means for “approval status” vs “access” in 2024
“Approval” means regulators authorized marketing. “Access” (whether patients can actually obtain it) can still vary in 2024 due to reimbursement decisions, formulary status, and launch timing in each country, even when the authorization exists at the European level.
---
Sources:
[1] https://www.drugpatentwatch.com/